{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:30:39Z","timestamp":1766050239536,"version":"3.41.2"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>This retrospective study aims to present the characteristics of Posner-Schlossman syndrome (PSS) relapse following inactivated COVID-19 vaccination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>From 2020 to 2022, 12 out of 106 PSS patients undergoing relapses after any dose of inactivated COVID-19 vaccines were enrolled. Medical histories, information on the vaccination and systemic adverse events were collected. Patients were treated with corticosteroids, intraocular pressure (IOP)-lowering drugs and systemic immunosuppressive agents (if needed). Daily regimen and release course were noted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The recurrence rate after vaccination was 11.32% (12\/106, 95% CI: 5.29%\u201317.35%) among 106 PSS patients we surveyed. All the 12 patients were inoculated with inactivated COVID-19 vaccines developed by Sinopharm, China. The mean time of relapse was 5.27 \u00b1 3.72 days (range: 1\u201313 days, median: 4 days). Higher IOP and more keratic precipitates (KPs) were seen in the relapse following vaccination (33.55 \u00b1 12.99 mmHg, 91.67% had KPs compared to 25.38 \u00b1 3.80 mmHg, 33.33% had KPs in previous relapse, <jats:italic>P<\/jats:italic> = 0.009). The mean release course was 30.71 \u00b1 34.74 days for the relapse following vaccination and 7.33 \u00b1 6.51 days for previous relapses. The attack frequency before and after vaccination was 3.56 \u00b1 2.07 and 9.11 \u00b1 7.34 times per year (<jats:italic>P<\/jats:italic> = 0.044). Higher daily doses of corticosteroids, IOP-lowering drugs and ganciclovir were needed to maintain stable course, though the difference did not reach statistical significance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>More frequent relapses and harder control of IOP were found in PSS relapse following COVID-19 vaccination. Ophthalmologists need to be aware of the group vulnerability and take precautions, though the pathogenesis is still under investigation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2022.1051378","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T06:04:40Z","timestamp":1673589880000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Posner-Schlossman syndrome relapse following inactivated COVID-19 vaccination in China"],"prefix":"10.3389","volume":"10","author":[{"given":"Qilian","family":"Sheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruyi","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xintong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangmei","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.survophthal.2016.12.005","article-title":"Posner-Schlossman syndrome","volume":"62","author":"Megaw","year":"2017","journal-title":"Surv Ophthalmol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0161-6420(01)00551-6","article-title":"Is Posner Schlossman syndrome benign?","volume":"108","author":"Jap","year":"2001","journal-title":"Ophthalmology."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.arcmed.2020.09.010","article-title":"Coronavirus Disease (COVID-19): current status and prospects for drug and vaccine development","volume":"52","author":"Ita","year":"2021","journal-title":"Arch Med Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1080\/10408363.2021.1979462","article-title":"The COVID-19 pandemic: viral variants and vaccine efficacy","volume":"59","author":"Ciotti","year":"2022","journal-title":"Crit Rev Clin Lab Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"602256","DOI":"10.3389\/fimmu.2020.602256","article-title":"COVID-19: Coronavirus vaccine development updates","volume":"11","author":"Zhao","year":"2020","journal-title":"Front Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1080\/09273948.2021.1976221","article-title":"Ocular adverse events after COVID-19 vaccination","volume":"29","author":"Ng","year":"2021","journal-title":"Ocul Immunol Inflamm."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1080\/09273948.2021.1962917","article-title":"Acute uveitis following COVID-19 vaccination","volume":"29","author":"ElSheikh","year":"2021","journal-title":"Ocul Immunol Inflamm."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jamaophthalmol.2021.3477","article-title":"Association of ocular adverse events with inactivated COVID-19 vaccination in patients in Abu Dhabi","volume":"139","author":"Pichi","year":"2021","journal-title":"JAMA Ophthalmol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40123-021-00338-1","article-title":"Ophthalmological considerations for COVID-19 vaccination in patients with inflammatory eye diseases and autoimmune disorders","volume":"10","author":"Chau","year":"2021","journal-title":"Ophthalmol Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3390\/vaccines10020342","article-title":"Ocular complications following vaccination for COVID-19: a one-year retrospective","volume":"10","author":"Haseeb","year":"2022","journal-title":"Vaccines."},{"key":"B12","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.it.2015.04.003","article-title":"Immune mechanisms in inflammatory and degenerative eye disease","volume":"36","author":"Perez","year":"2015","journal-title":"Trends Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/09273948.2017.1394471","article-title":"Clinical features of CMV-associated anterior uveitis","volume":"26","author":"Chan","year":"2018","journal-title":"Ocul Immunol Inflamm."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0175519","DOI":"10.1371\/journal.pone.0175519","article-title":"Serum Th1 and Th17 related cytokines and autoantibodies in patients with Posner-Schlossman syndrome","volume":"12","author":"Zhao","year":"2017","journal-title":"PLoS ONE."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e0199301","DOI":"10.1371\/journal.pone.0199301","article-title":"Different composition of intraocular immune mediators in Posner-Schlossman-syndrome and Fuchs' Uveitis","volume":"13","author":"Pohlmann","year":"2018","journal-title":"PLoS ONE."},{"key":"B16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/vaccines9121404","article-title":"Ocular manifestations after receiving COVID-19 vaccine: a systematic review","volume":"2021","author":"Lee","year":"2021","journal-title":"Vaccines."},{"key":"B17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s40123-021-00415-5","article-title":"The eye of the storm: COVID-19 vaccination and the eye","volume":"11","author":"Ng","year":"2022","journal-title":"Ophthalmol Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s42399-021-00985-2","article-title":"Post coronavirus disease (COVID-19) reactivation of a quiescent unilateral anterior uveitis","volume":"3","author":"Sanjay","year":"2021","journal-title":"SN Compr Clin Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10059-009-0015-1","article-title":"Host responses from innate to adaptive immunity after vaccination: molecular and cellular events","volume":"27","author":"Kang","year":"2009","journal-title":"Mol Cells."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/S0140-6736(03)14802-7","article-title":"Vaccination and autoimmune disease: what is the evidence?","volume":"362","author":"Wraith","year":"2003","journal-title":"Lancet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1080\/09273948.2019.1626188","article-title":"Vaccine-associated uveitis","volume":"27","author":"Cunningham ET","year":"2019","journal-title":"Ocul Immunol Inflamm."},{"key":"B22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/IIO.0b013e31822d6ab4","article-title":"Infectious theories of Posner-schlossman syndrome","volume":"51","author":"Takusagawa","year":"2011","journal-title":"Int Ophthalmol Clin."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.survophthal.2021.12.006","article-title":"Clinical characteristics and treatment outcomes of cytomegalovirus anterior uveitis and endotheliitis: a systematic review and meta-analysis","volume":"67","author":"La Distia Nora","year":"2022","journal-title":"Surv Ophthalmol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000309939","article-title":"Cytomegalovirus panuveitis with infection of corneo-trabecular endothelium in AIDS","volume":"197","author":"Daicker","year":"1988","journal-title":"Ophthalmologica."},{"key":"B25","doi-asserted-by":"publisher","first-page":"607966","DOI":"10.3389\/fimmu.2021.607966","article-title":"Polymorphisms and circulating plasma protein levels of immune checkpoints (CTLA-4 and PD-1) are associated with posner-schlossman syndrome in Southern Chinese","volume":"12","author":"Huang","year":"2021","journal-title":"Front Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"6687929","DOI":"10.1155\/2021\/6687929","article-title":"The analysis of dynamic changes and prognosis of Posner-Schlossman syndrome with cytomegalovirus infection and antiviral therapy","volume":"2021","author":"Sheng","year":"2021","journal-title":"J Ophthalmol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"848820","DOI":"10.3389\/fmed.2022.848820","article-title":"2% Ganciclovir eye drops control Posner-Schlossman syndrome relapses with\/without cytomegalovirus intraocular reactivation","volume":"9","author":"Sheng","year":"2022","journal-title":"Front Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09273948.2021.1952277","article-title":"Iris depigmentation in the prediction of cytomegalovirus anterior uveitis","volume":"20","author":"Kam","year":"2021","journal-title":"Ocul Immunol Inflamm."},{"key":"B29","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ajo.2021.12.015","article-title":"Cytomegalovirus-positive posner-schlossman syndrome: impact on corneal endothelial cell loss and retinal nerve fiber layer thinning","volume":"237","author":"Lenglinger","year":"2022","journal-title":"Am J Ophthalmol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ijid.2021.09.075","article-title":"Bilateral uveitis after inoculation with COVID-19 vaccine: a case report","volume":"113","author":"Pan","year":"2021","journal-title":"Int J Infect Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.3390\/vaccines10101680","article-title":"There is no evidence that inactivated COVID-19 vaccines increase risks of uveitis flare","volume":"10","author":"Song","year":"2022","journal-title":"Vaccines."},{"key":"B32","doi-asserted-by":"publisher","first-page":"823346","DOI":"10.3389\/fmed.2021.823346","article-title":"Case report: associated ocular adverse reactions with inactivated COVID-19 vaccine in China","volume":"8","author":"Pang","year":"2022","journal-title":"Front Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.4103\/ijo.IJO_1435_21","article-title":"COVID-19 vaccine-associated reactivation of uveitis","volume":"69","author":"Jain","year":"2021","journal-title":"Indian J Ophthalmol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"749","DOI":"10.21037\/atm.2019.11.70","article-title":"The genetic contribution of HLA-E*01:03 and HLA-E*01:03-G*01:01 to Posner-Schlossman syndrome in southern Chinese","volume":"7","author":"Huang","year":"2019","journal-title":"Ann Transl Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/tan.13058","article-title":"A novel HLA-G allele, HLA-G*01:01:01:07, was identified in a Chinese patient with Posner-Schlossman syndrome","volume":"90","author":"Zhao","year":"2017","journal-title":"HLA."},{"key":"B36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12348-021-00251-5","article-title":"Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, following anti-SARS-CoV-2 vaccination","volume":"11","author":"Papasavvas","year":"2021","journal-title":"J Ophthalmic Inflamm Infect."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1097\/IAE.0000000000003277","article-title":"Uveitis after the BNT162b2 mRNA vaccination against SARS-CoV-2 infection: a possible association","volume":"41","author":"Rabinovitch","year":"2021","journal-title":"Retina."},{"key":"B38","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40265-021-01480-7","article-title":"BNT162b2 mRNA COVID-19 vaccine: first approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs."},{"key":"B39","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41577-021-00578-z","article-title":"Immunological mechanisms of vaccine-induced protection against COVID-19 in humans","volume":"21","author":"Sadarangani","year":"2021","journal-title":"Nat Rev Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3389\/fimmu.2018.00600","article-title":"Novel platforms for the development of a universal influenza vaccine","volume":"9","author":"Kumar","year":"2018","journal-title":"Front Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.ijbiomac.2021.08.076","article-title":"SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: a review","volume":"188","author":"Fathizadeh","year":"2021","journal-title":"Int J Biol Macromol."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.1051378\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T06:04:42Z","timestamp":1673589882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.1051378\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":41,"alternative-id":["10.3389\/fpubh.2022.1051378"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2022.1051378","relation":{},"ISSN":["2296-2565"],"issn-type":[{"type":"electronic","value":"2296-2565"}],"subject":[],"published":{"date-parts":[[2023,1,13]]},"article-number":"1051378"}}